language_icon
EN
HI

Caplin Point Laboratories Share price

CAPLIPOINT

2025.9

9.30 (0.46%)
NSE
BSE
Last updated on 21 May, 2026 | 15:46 IST
Today's High

2050.00

Today's Low

1998.00

52 Week Low

1500.30

52 Week High

2395.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Caplin Point Laboratories Chart

Caplin Point Laboratories Share Key Metrics

Volume
97506.00
Market Cap
15399.21 CR
LTQ@LTP
7@2025.90
ATP
2023.79
Var Margin
18.4 %
Circuit Range
1613.3-2419.9
Delivery %
42.59 %
Value
19.73 CR
ASM/GSM
No
Market Lot
1

Summary

Caplin Point Laboratories share price is ₹2025.9 as of 22 May, 2026. The stock Caplin Point Laboratories intraday movement has stayed between ₹1998.00 and ₹2050.00, while on a 52-week basis,Caplin Point Laboratories price 52 week high is ₹2395.00 & its 52 week low is ₹1500.30.
In terms of trading activity, Caplin Point Laboratories has recorded a volume of 97506 shares, The Caplin Point Laboratories has a market cap of ₹76011696 CR. The stock’s Average Traded Price (ATP) stands at ₹2023.79, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 7 @ ₹2025.90.
Caplin Point Laboratories operates within a circuit range of ₹1613.30 – ₹2419.90, with a Value of ₹19.73 CR. The Delivery Percentage for the day is 42.59%. Additionally, Caplin Point Laboratories currently falls under the No framework, and trades with a market lot size of 1.

Caplin Point Laboratories Fundamentals

View More
P/E Ratio

23.9

P/B Ratio

4.27

Div. Yield

0.2

Sector P/E

71.81

Sector P/B

3.44

Sec. Div. Yield

0.55

Caplin Point Laboratories Resistance and Support

Pivot 2031.5

Resistance

First Resistance

2053.2

Second Resistance

2089.8

Third Resistance

2111.5

Support

First Support

1994.9

Second Support

1973.2

Third Support

1936.6

Caplin Point Laboratories Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

70.57%

Mutual Fund

2.02%

Insurance

0.01%

Foreign Institutional Investors

6.15%

Domestic Institutional Investors

0.11%

Retail

21.14%

Others

0%

Total Promoters
MAR '26
70.57%

Caplin Point Laboratories Corporate Actions

DateAgenda
2026-05-14Audited Results & Interim Dividend
2026-02-05Quarterly Results
2025-11-06Quarterly Results
2025-11-05Quarterly Results
2025-08-07Quarterly Results
2025-05-15Audited Results & Interim Dividend
2025-02-07Quarterly Results

Caplin Point Laboratories News

Caplin Point Laboratories Limited

Caplin Steriles, a subsidiary of Caplin Point Laboratories, secured final USFDA approval for its Foscarnet Sodium Injection ANDA. This approval allows the company to launch a generic version of a drug with US sales of approximately $15 million.
May 14 2026 19:05:00

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, secured USFDA final approval for Foscarnet Sodium Injection (6000 mg/250 mL), a generic antiviral drug. This approval opens up access to the US market for a product with approximately $15 million in annual sales.
May 14 2026 19:05:00

Caplin Point Laboratories Limited

Caplin Point declared an interim dividend of Rs. 4 per equity share for FY26. The record date is May 30, 2026, and payment will be made by June 13, 2026.
May 14 2026 18:05:00

Caplin Point Laboratories Ltd - 524742 - Corporate Action-Board approves Dividend

Caplin Point declared an interim dividend of ₹4.00 per equity share (200% on ₹2 face value) for FY26. The record date for eligibility is May 30, 2026, impacting shareholders for the fiscal year ending March 31, 2026.
May 14 2026 13:05:00

Caplin Point Laboratories Ltd - 524742 - Board Meeting Outcome for For Meeting Held On May 14, 2026

Caplin Point Laboratories board declared an interim dividend of ₹4.00 per share and approved Q4 and FY26 consolidated results. For Q4 FY26, total revenue rose 19% YoY to ₹628.52 cr, and net profit increased 19% YoY to ₹172.88 cr. The full-year FY26 saw total revenue grow 13.2% YoY to ₹2,302.73 cr and net profit rise 20.1% YoY to ₹649.73 cr, with a record date for dividend set for May 30, 2026.
May 14 2026 13:05:00

Caplin Point Laboratories Limited

Caplin Point Laboratories will hold a board meeting on May 14, 2026. The agenda includes considering annual financial results for FY26 and the declaration of an interim dividend, if any, along with fixing its record date.
May 07 2026 16:05:00

Caplin Point Laboratories Limited

CAPLIN POINT LABORATORIES LIMITED board will convene on May 14, 2026, to review and approve the audited annual standalone and consolidated financial results for the financial year ending March 2026. Additionally, the board will consider declaring an interim dividend for shareholders.
May 07 2026 16:05:00

Caplin Point Laboratories Ltd - 524742 - Board Meeting Intimation for Approval Of Financial Results And Declaration Of Interim Dividend, If Any, Approved By The Board.

Caplin Point Laboratories has scheduled a board meeting for May 14, 2026. The agenda includes the consideration and approval of the annual audited financial results for FY2025-26 and the potential declaration of an interim dividend, along with fixing its record date.
May 07 2026 16:05:00

Caplin Point Laboratories Limited

Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP. This approval opens access to the US market for a drug with annual sales of approximately $71 million.
May 05 2026 12:05:00
Read More

About Caplin Point Laboratories

NSE : 3906  
BSE : 524742  
ISIN : INE475E01026  

The Company was incorporated on 16th April 1990 under the Act as a Private Limited Company under the name of CAPLIN POINT LABORATORIES PRIVATE LIMITED. The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED effective 23rd April 1993. The Company has adopted a new set of Articles on 12th March 1993 as applicable to public limited companies.The Company was incorporated as an extension of a pharmaceutical manufacturing unit started by M/s Triwin Pharmaceuticals the first pharmaceutical venture started by Mr. P C Partheeban (presently the Managing Director) Mr. T Palanisamy and Mr. S Karunakaran in the year 1987 as a partnership firm. In the year 1990 the Company was incorporated by the partners of the aforesaid firm alongwith Mr. B A Ahmed. Soon thereafter Mr. S Jayaraman joined the Board to take charge of production. Recently the Board has been recast with all Directors except Mr.P.C.Partheeban making room for broadbasing the Board. The resigning Directors have taken positions as Senior level Managers in the Company.M/s Triwin Pharmaceuticals was engaged in the business of manufacture of Tablets Liquid orals and Capsules (Non-Antibiotic) and Import Sales of family planning andcertain life saving drugs. The said firm also started theExport of manufactured formulations in the year 1992-93.Even after the incorporation of the Company the firm continued its manufacturing sales and export of Tablets Liquid orals and Capsules (Non-Antibiotic) and business of import sales while the Company started the manufacture of Ointments Oral Powders and Capsules (Antibiotic).The said firm has since been taken over by the Company with effect from 1st September 1993 with the objective of consolidation of the business of the Company into a single larger entity for setting up the Project envisaged. All the assets and liabilities of the firm were taken over at book values as at 31st August 1993. The Company''s turnover in future shall comprise of the sales generated from the manufacturing faculties of the erstwhile firm also. Salient terms of the takeover Agreement executed by the Company with M/s. Triwin Pharmacuticals (''Triwin'') are as follows.a. Transfer and vesting of assets and liabilities of Triwin in the Company All the assets and liabilities of Triwin including itsfactory located at No. 44 Kamakoti Nagar AnnexeValasaravakkam Madras 600 087 on going business basis aretransferred at book values as on 31st August 1993.b. Net consideration for the transfer of assets and liabilities Consideration payable by the Company shall be the net worthof Triwin (excluding good will) estimated at Rs.3162000on the basis of its audited accounts as at 31st August1993.c. Continuance of Business In the post-transfer stage the Company to continue to dothe business then carried on by Triwin (including themanufacturing operation) and Triwin shall suspend all theproduction/sales activities hitherto carried on by them.d. Discharge of Purchase consideration The Company to issue at par its Shares credited as fullypaid-up to the partners of Triwin for an aggregate nominalvalue of Rs. 3162000 (Rupees Thirty One lacs Sixty TwoThousand only) in the proportion of amounts lying to thecredit of the respective capital/current accounts as on 31st August 1993.

Read More

Caplin Point Laboratories Management

NamePosition
G VenkatramGeneral Counsel & Company Secretary, Compliance Officer
C C PaarthipanChairman
View More

Caplin Point Laboratories FAQs

The Buying Price of Caplin Point Laboratories share is 2025.9 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Caplin Point Laboratories stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Caplin Point Laboratories, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Caplin Point Laboratories shares is 23.9. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Caplin Point Laboratories shares is 4.27. Useful to assess the stock's value relative to its book value.

To assess Caplin Point Laboratories’s valuation compare Sector P/E, P/B which are 71.81 & 3.44 with sector averages, along with growth rates and financial metrics.

The Market Cap of Caplin Point Laboratories is 15399.21 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Caplin Point Laboratories share price is 2395.00 & 1500.30. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Caplin Point Laboratories belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost